Felbatol and Fycompa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Felbatol (felbamate) and Fycompa (perampanel). Common drug interactions include urinary tract infection among females and peripheral swelling among males.

The phase IV clinical study analyzes what interactions people have when they take Felbatol and Fycompa. It is created by eHealthMe based on reports of 32 people who take the same drugs from the FDA, and is updated regularly.

What is Felbatol?

Felbatol has active ingredients of felbamate. It is often used in epilepsy. eHealthMe is studying from 906 Felbatol users. Check the latest studies of Felbatol.

What is Fycompa?

Fycompa has active ingredients of perampanel. eHealthMe is studying from 4,387 Fycompa users. Check the latest studies of Fycompa.



On Jul, 14, 2026

32 people who take Felbatol and Fycompa together, and have interactions are studied.

Felbatol and Fycompa drug interactions.

What are the common drug interactions of Felbatol and Fycompa, by gender? *:

female:

  1. Urinary tract infection
  2. Ear infection
  3. Simple partial seizures (seizures which affect only a small region of the brain)
  4. Upper respiratory tract infection
  5. Fall
  6. Hand fracture
  7. Irritability
  8. Pneumonia
  9. Decreased immune responsiveness
  10. Influenza

male:

  1. Peripheral swelling
  2. Fatigue (feeling of tiredness)
  3. Urine output decreased
  4. Aggression
  5. Anaemia (lack of blood)
  6. Clonic convulsion (long lasting seizure)
  7. Flushing (the warm, red condition of human skin)
  8. Pain
  9. Abnormal behaviour
  10. Anger

What are the common drug interactions of Felbatol and Fycompa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Decreased immune responsiveness
  2. Influenza
  3. Pneumonia
  4. Respiratory syncytial virus infection (viral disease of respiratory system)

10-19:

n/a

20-29:

  1. Haematoma (collection of blood outside the blood vessels)
  2. Aggression
  3. Diarrhoea
  4. Drug ineffective
  5. Irritability
  6. Memory impairment
  7. Nausea (feeling of having an urge to vomit)
  8. Viral infection
  9. Vitamin d deficiency
  10. Vomiting

30-39:

  1. Abnormal behaviour
  2. Aggression
  3. Anger
  4. Cellulitis (infection under the skin)
  5. Hypertension (high blood pressure)

40-49:

  1. Cerebellar atrophy (degeneration of the section of the brain responsible for balance, voluntary muscle movements)
  2. Dementia (madness)
  3. Drug intolerance (drug sensitivity)
  4. Feeling drunk
  5. Joint dislocation (a joint position is changed from normal position)
  6. Respiratory disorder (respiratory disease)
  7. Somnolence (a state of near-sleep, a strong desire for sleep)
  8. Ammonia increased
  9. Pneumonia
  10. Urinary tract infection

50-59:

  1. Ear infection
  2. Simple partial seizures (seizures which affect only a small region of the brain)
  3. Upper respiratory tract infection
  4. Urinary tract infection
  5. Fall
  6. Hand fracture
  7. Irritability

60+:

n/a

What are the existing conditions these people have? *

  1. Immunodeficiency: 7 people, 21.88%
  2. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 6 people, 18.75%
  3. Schizoaffective Disorder (a mental disorder characterized by disordered thought): 3 people, 9.38%
  4. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 9.38%
  5. Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 9.38%
  6. Depression: 3 people, 9.38%
  7. Constipation: 3 people, 9.38%
  8. Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Felbatol and Fycompa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Felbatol and Fycompa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Felbatol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Fycompa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Felbatol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Fycompa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on felbamate and perampanel (the active ingredients of Felbatol and Fycompa, respectively), and Felbatol and Fycompa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: